Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial

benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial

Novartis AG (NYSE:NVS) on Thursday released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing giant cell arteritis (GCA).
Giant cell arteritis is an inflammation of the lining of the arteries. It often affects the arteries…

This story appeared on benzinga.com, 2025-07-03 13:00:20.
The Entire Business World on a Single Page. Free to Use →